SAN DIEGO--(BUSINESS WIRE)--Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Corvidia Therapeutics Inc. The non-exclusive license grants Corvidia rights to use the AlivaMab Mouse for antibody drug discovery and development. Financial terms of the license include an upfront payment, development milestones and a royalty on product sales.
About Ablexis, LLC
Ablexis, LLC created and commercializes
the AlivaMab Mouse technology, a unique, patented next generation
transgenic mouse platform for human therapeutic antibody discovery.
Ablexis has non-exclusively licensed the AlivaMab Mouse technology to
multiple companies, including global pharmaceutical companies, public
and private biotechnology companies and other entities. Ablexis
continues making the AlivaMab Mouse available via non-exclusive
licenses. For more information, visit www.ablexis.com.
For inquiries about licensing AlivaMab Mouse, contact us at info@ablexis.com.
